We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine



Licensing of the anti-PD-1 antibody
from China's Jiangsu Hengrui Medicine Co., Ltd.

  • Indication
    Solid cancer
  • Development stage
    Preparing for new drug approval


Camrelizumab's competitive advantage

Superior effectiveness compared to existing immune checkpoint inhibitory antibody treatments in certain carcinomas

Camrelizumab blocks PD-1, allowing T cells to recover immune responses to tumors, resulting in tumor immune responses.
Currently, Keytruda and Opdivo are the only marketed immune checkpoint inhibitors in Korea.
As of 2019, the size of the domestic market is 190.3 billion won, and annual treatment costs of 100 million won are required for each patient.
Camrelizumab seeks to strengthen the competition and thereby provide a health economic benefit to the Korean market